Phio Pharmaceuticals: Up on positive data from cancer therapy platform study

Phio Pharmaceuticals

04/06/2021 14:05

** Shares of biotech co  PHIO.O  rise 3.6% to $2.25
premarket
    ** Co reports positive data from a study of its INTASYL
platform in mice  urn:newsml:reuters.com:*:nPn8v0CZma
    ** INTASYL is self-delivering therapy platform, and the new
data show how INTASYL can be easily deployed to target multiple
proteins - PHIO 
    ** Co says INTASYL used as a dual-targeting platform showed
complete tumor responses in a hepatoma, or liver cancer, model,
and significantly outperformed efficacy of other approaches,
including antibody treatments towards the same targets
    ** Platform also resulted in a superior safety profile - co
    ** As of last close, PHIO stock down ~19% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com;))